← Back to all trials
Not Yet Recruiting
NCT05733416
Intensive Cancer Screening After Cryptogenic Stroke
Conditions: Occult Cancer
Sex: All
Ages: 18 Years – N/A
Phase: NA
Enrollment: 45
Sponsor: Ottawa Hospital Research Institute
Summary
The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET/CT in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke.
Eligibility Criteria
Inclusion Criteria:(a) adults ≥18 years, (b) presenting to the Ottawa Hospital Stroke Prevention Clinic or the Ottawa Hospital Neurovascular Unit with a first cryptogenic ischemic stroke after advanced evaluation as per American Heart Association guidelines27 and Saver approach8 (maximum 3 months after stroke), (c) patient or delegate willing and able to provide informed consent.Exclusion Criteria:(a) contraindications to FDG PET/CT (pregnancy or unable to lie still in bed for 20 minutes), (b) or active cancer or previous cancer diagnosis (other than basal or squamous cell carcinoma of the skin)
Source: ClinicalTrials.gov (NCT05733416). StuddyBuddy aggregates publicly available trial information.
